ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

Why Did DeVita Resign MSK Post? Clash Of Style, Other Serious Issues Pointed To By Colleagues

June 7, 1991

In Brief: Fabien Calvo named chief scientific officer of Cancer Core Europe

December 19, 2014

MSK Withdraws Form Breast Cancer Nutrition Study Over Chemotherapy Issue; Program Still “Going Well”

June 21, 1985

Phase III Study Evaluating Halaven Fails To Meet Primary Endpoints

July 27, 2012

NCI Prepares For Intramural Program Review

June 27, 2014

NCI’s use of Cancer Dialogue for biospecimen network blueprint raises legal, procedural questions.

December 12, 2003